• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Approach to mechanism of pathogenesis in MDS using DNA methylation analysis

Research Project

Project/Area Number 17K09000
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Laboratory medicine
Research InstitutionKawasaki Medical School

Principal Investigator

Tsujioka Takayuki  川崎医科大学, 医学部, 准教授 (50330551)

Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
KeywordsMDS / DNMTIs / 白血病 / DNAメチル化 / コレステロール-25-ハイドロキシラーゼ / 25-オキシステロール / CH25H / 25-OHC / 25-OHC / 臨床検査医学
Outline of Final Research Achievements

DNA methyltransferase inhibitors (DNMT inhibitors) are administered for high-risk MDS, but their action mechanisms are not fully understood. We performed a genome-wide DNA methylation assay and focused on cholesterol 25-hydroxylase (CH25H) among the genes whose expression was up-regulated and whose promoter region was hypomethylated after decitabine (DAC) treatment. CH25H produces 25-hydroxycholesterol(25-OHC). Although CH25H mRNA expression level was low in MDS/leukemia cell lines, exposure to DNMT inhibitors enhanced CH25H mRNA expression. The promoter region of CH25H was hypermethylated in HL-60 and MDS-L cells, but DAC induced their hypomethylation together with increased CH25H mRNA expression, activation of CH25H-oxysterol pathway, 25-OHC production and apoptotic cell death.The present study raises a possibility that DNMT inhibitors activate CH25H-oxysterol pathway by their hypomethylating mechanism and induce leukemic cell death.

Academic Significance and Societal Importance of the Research Achievements

骨髄異形成症候群(MDS)は予後良好の血液悪性腫瘍である。治癒は造血幹細胞移植しかないが, 高齢発症が多いため, 移植適応外患者の治療薬について以前から切望されてきた。最近, MDSに対するDNAメチル化阻害薬(DNMTIs)の有用性が指摘されているが, 作用機序の詳細, ターゲットになる遺伝子は同定されていない。今回, 我々は網羅的遺伝子発現解析と次世代シーケンサーによる網羅的メチル化解析を行い, コレステロール-25-ハイドロキシラーゼ(CH25H)の発現増加に注目した。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (1 results)

All Other

All Remarks (1 results)

  • [Remarks] 川崎医科大学検査診断学教室

    • URL

      http://www.kawasaki-m.ac.jp/lh/research_act.htm

    • Related Report
      2019 Annual Research Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi